MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC. (MDGL): 23 pipeline candidates · 3 upcoming catalysts · ~16 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.1 months
D/E 1.26 · 26% dilution
Lead: Phase 3
23 candidates
3 upcoming, next in ~197d
0 buys · 97 sells (180d)
A transparent, data-derived signal for MADRIGAL PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.5B
Cash
$232.2M
Quarterly Burn
$167.4M
Runway
16.1 mo
Revenue
$311.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 1 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
| 100 mg resmetirom | Phase 3 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
380
Total value held
$12.51B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,037,294 | $2.10B |
| baker bros. advisors lp | 2,141,701 | $1.12B |
| rtw investments, lp | 1,993,687 | $1.04B |
| vanguard capital management llc | 1,654,288 | $866.0M |
| blackrock, inc. | 1,559,965 | $816.6M |
| vanguard portfolio management llc | 841,145 | $440.3M |
| wellington management group llp | 694,958 | $363.8M |
| state street corp | 609,525 | $319.1M |
| citadel advisors llc | 602,543 | $315.4M |
| fmr llc | 511,728 | $267.9M |
Showing top 10 of 380 institutional holders of MADRIGAL PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MADRIGAL PHARMACEUTICALS, INC.'s pipeline?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MADRIGAL PHARMACEUTICALS, INC.'s lead drug candidate?
MADRIGAL PHARMACEUTICALS, INC.'s most advanced tracked candidate is 100 mg resmetirom (Phase 3) for MASH - Metabolic Dysfunction-Associated Steatohepatitis; Non-Alcoholic Fatty Liver Disease; NASH.
What is MADRIGAL PHARMACEUTICALS, INC.'s next catalyst?
MADRIGAL PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L" — expected January 1, 2027.
What is MADRIGAL PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MADRIGAL PHARMACEUTICALS, INC. has approximately 16.1 months of cash runway.
What is MADRIGAL PHARMACEUTICALS, INC.'s market capitalization?
MADRIGAL PHARMACEUTICALS, INC.'s market capitalization is approximately $11.5B.
Get the full picture on MADRIGAL PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.